Principal Financial Group Inc. Sells 215,555 Shares of Boston Scientific Corporation $BSX

Principal Financial Group Inc. trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 11.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,637,238 shares of the medical equipment provider’s stock after selling 215,555 shares during the period. Principal Financial Group Inc. owned approximately 0.11% of Boston Scientific worth $159,844,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Riverwater Partners LLC boosted its stake in Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after buying an additional 98 shares during the period. Gerber Kawasaki Wealth & Investment Management lifted its holdings in shares of Boston Scientific by 3.8% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC boosted its stake in shares of Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares during the period. IVC Wealth Advisors LLC grew its holdings in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 102 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its position in Boston Scientific by 3.9% in the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 103 shares during the period. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. The Goldman Sachs Group restated a “buy” rating and set a $112.00 target price on shares of Boston Scientific in a research report on Friday, January 9th. Evercore ISI set a $112.00 price objective on Boston Scientific in a report on Monday, January 5th. Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Thursday, January 15th. BTIG Research reissued a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Finally, Royal Bank Of Canada upped their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $123.89.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of BSX stock opened at $93.58 on Monday. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $95.21 and a two-hundred day simple moving average of $99.47. The stock has a market capitalization of $138.72 billion, a price-to-earnings ratio of 50.04, a P/E/G ratio of 1.66 and a beta of 0.67.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.